Filing Details
Entrada Therapeutics, Inc. (NASDAQ:TRDA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 05, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:TRDA
Entrada Therapeutics, Inc. (TRDA) Files Quarterly Report for Q0
Filing Details Entrada Therapeutics, Inc. (NASDAQ:TRDA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 05, 2026. The Healthcare…
Market Context
Entrada Therapeutics, Inc.'s stock currently trades at $7.06 with a market capitalization of $413.5M.
The 10-Q provides Entrada Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Entrada Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TRDA Stock Page
Frequently Asked Questions
Where can I read TRDA's SEC filings?
Browse all filings on our TRDA SEC filings page.
What types of SEC filings does Entrada Therapeutics, Inc. file?
Public companies like Entrada Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.